Newly Diagnosed AML With FLT3 Activating Mutations Clinical Trials

Newly Diagnosed AML With FLT3 Activating Mutations

Explore clinical trials studying Newly Diagnosed AML With FLT3 Activating Mutations. Study availability and eligibility vary by location and protocol.

1 public trial 0 recruiting studies

Newly Diagnosed AML With FLT3 Activating Mutations trial results

Completed

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

NCT02283177

Conditions: Newly Diagnosed AML With FLT3 Activating Mutations
Locations: City of Hope Medical Center Duarte, California, United States

University of Iowa Hospitals and Clinics Iowa City, Iowa, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

Roswell Park Cancer Institute Buffalo, New York, United States

View Trial Details